StockData
Hepion Pharmaceuticals, Inc. logo

Hepion Pharmaceuticals, Inc. (HEPA) company profile

HEPAOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as CTRVP
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q/A on Nov 17, 2026Score 1/30
$0.10−0.00 (-1.45%)

Close on Oct 19, 2026Market cap $7.26MP/E –Yield –

About Hepion Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Hepion Pharmaceuticals, Inc. operates as a medical diagnostic company focused on diagnostic solutions. The company previously concentrated on developing drug therapies for chronic liver conditions, specifically its cyclophilin inhibitor rencofilstat, before divesting all related patent assets, clinical data, and drug materials. Currently, Hepion in-licenses diagnostic tests covering conditions such as celiac disease, respiratory multiplex infections, Helicobacter pylori, and hepatocellular carcinoma, alongside licensed liver disease diagnostic assets. It targets healthcare markets seeking clinical diagnostic tools.

The company maintains its principal executive offices in Morristown, New Jersey. Its licensed tests for celiac disease, respiratory multiplex, and Helicobacter pylori hold CE marks, making them eligible for commercial sale within the European Union and other participating territories that recognize CE certification, while excluding the United States. Hepion does not possess internal commercialization, sales, marketing, or manufacturing facilities, relying instead on external arrangements and collaborations to advance and distribute its diagnostic product portfolio across authorized regional markets.

Summary of the business section of Hepion Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Hepion Pharmaceuticals, Inc.
Founded
2013
Headquarters
Red Bank, NJ
Address
34 Shrewsbury Ave., Suite 1d 07701
Phone
(732) 902-4000
Website
hepion.com
Employees
2, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Grassi & Co., CPAs, P.C, Jericho, New York

Stock & identifiers

Ticker
HEPA
Other tickers
CTRVP
Exchange
OTC
IPO date
Feb 10, 2014
Shares outstanding
90M, Aug 10, 2026
Public float
$900.00K, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-50 reverse, Mar 18, 2025; 1-for-20 reverse, May 11, 2023; 1-for-70 reverse, Jun 3, 2019; 1-for-8 reverse, May 29, 2018
SEC CIK
1583771
FIGI
BBG005Y0S0J9
Share class FIGI
BBG005Y0S0K7
EIN
46-2783806

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Sireesh AppajosyulaChief Executive Officer, Director3,250,000
Vincent S. LoPrioreExecutive Chairman, Director30,500,000
Gary S. StetzChief Financial Officer, Director4,500,000
Chase LoPrioreVP, Corp. Dev., Director1,250,000
James Gordon LiddyDirector–
Danina FisherDirector200,000
Gary S. Stetz IIDirector500,000
Michael J. PurcellDirector3,250,000
Collective Corp. GravitasDirector25,000,000

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryTotalvs. prior year
John Brancaccio
Former Interim Chief Executive Officer and Chief Financial Officer
$232.50K$232.50K-54%
Kaouthar Lbiati
Former Chief Executive Officer
$198.02K$198.02K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had two employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 9, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 28, 2026Auditor changeChange in certifying accountant (8-K Item 4.01)
Jul 22, 2025DelistingNotice of delisting from exchange (Form 25)
May 15, 2025Late filingNotification of late filing
May 12, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 17, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 1, 2025Late filingNotification of late filing
Mar 20, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 15, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 21, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 5, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 15, 2024Late filingNotification of late filing
Apr 1, 2024Late filingNotification of late filing
Jan 3, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 14, 2023Late filingNotification of late filing
Apr 3, 2023Late filingNotification of late filing
Jun 6, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 31, 2022Late filingNotification of late filing
Jul 23, 2019Name changeName changed from ContraVir Pharmaceuticals, Inc. to Hepion Pharmaceuticals, Inc.
Mar 19, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 4, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 5, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 8, 2017Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 9, 2017Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 13, 2016Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 13, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 24, 2015ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?